New drug may offer better protection against virus after kidney transplant
Prevention
Not yet recruiting
This study tests if letermovir can prevent cytomegalovirus (CMV) infection in kidney transplant patients as well as the standard drug valganciclovir. About 300 CMV-positive adults will receive letermovir after transplant, and their results will be compared to past patients who to…
Phase: PHASE4 • Sponsor: Elisabeth Kincaide • Aim: Prevention
Last updated May 17, 2026 10:26 UTC